Dong-A ST Co., Ltd. (KRX:170900)

Market Cap	424.57B +0.3%
Revenue (ttm)	808.78B +15.9%
Net Income	-28.59B
EPS	-2,970.54
Shares Out	9.62M
PE Ratio	n/a
Forward PE	11.18
Dividend	666.67 (1.56%)
Ex-Dividend Date	Mar 10, 2026

Volume	9,837
Average Volume	16,170
Open	43,650
Previous Close	42,650
Day's Range	43,250 - 44,100
52-Week Range	38,952 - 56,381
Beta	0.50
RSI	46.52
Earnings Date	Apr 29, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. for lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for ovarian hyperstimulation and anovulation; Growtropin II Inj./AQ /cartridge to treat growth failure d...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 1,679
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 170900

Financial Performance

In 2025, Dong-A ST's revenue was 808.78 billion, an increase of 15.89% compared to the previous year's 697.87 billion. Losses were -28.59 billion, 2237.8% more than in 2024.